| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8536768 | Pharmacology & Therapeutics | 2018 | 77 Pages |
Abstract
Here we will describe the complex interplay between the genetic and clinical-pathological features of MSI/dMMR tumors and the cancer immunotherapy, with a focus on the predictive and prognostic role of MMR status for immune checkpoint inhibitors (ICIs) and providing some suggestions on how to conceive better predictive markers for immunotherapy in the next future.
Keywords
NGSHNPCCNCCNEpCAMMMRMSIMSH2IPIDFSMSSIpilimumabMSH6PMS2dMMRpMMRNCICTLA-4FDA5-FUMSI-LMSI-HCD28mCRCPD-1CTLORRNivolumabPD-L1PFscytotoxic T-lymphocytescytotoxic T lymphocyte antigen-4ImmunohistochemistryIHCICIDisease free survivalProgression free survivaloverall survivalMicrosatellite instabilitymicrosatellite instability-highmismatch repairNext-generation sequencingCinmicrosatellite stableFood and Drug AdministrationEndometrial cancerColorectal cancerNSCLCNon-small cell lung cancerMetastatic colorectal cancerGastric cancerHereditary Nonpolyposis Colorectal CancerLynch syndromeNational Comprehensive Cancer Network5-fluorouracilprogrammed cell death ligand 1ManaMHCmajor histocompatibility complexprogrammed cell death 1Immune checkpoint inhibitorNational Cancer Instituteepithelial cell adhesion moleculemegabaseoverall response ratehazard ratiopolymerase chain reactionPCRcomplete responseCRCGlioblastoma
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Marina Baretti, Dung T. Le,